Management of melasma (dark patches on face) with unani formulatio
- Conditions
- Health Condition 1: L811- ChloasmaHealth Condition 2: L81- Other disorders of pigmentation
- Registration Number
- CTRI/2019/05/019056
- Lead Sponsor
- Jamia Hamdard
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients of all genders, belonging to 18 to 60 years age group and willing to participate in the trial voluntarily
Clinically diagnosed patients of epidermal melasma using Woodâ??s lamp examination (340-400 nm)
Patients willing to sign the informed consent form
Pregnant and lactating women
Female patient using oral contraceptives and hormonal intrauterine devices.
Patients treated with tretinoin through the last 3 weeks
Patients treated with hydroquinone through the last 6 months before entering the study
Patients who have used any other bleaching creams or topical steroid creams for at least 4 weeks before entering the study
Patients who undergone any laser therapies and chemical peeling
Having used or consuming photosensitizing substances in past 4 weeks
Patients with drug or alcohol addiction
Patient having any endocrine or auto-immune disease
Patients with Diabetes mellitus, renal insufficiency, severe liver, spleen, or heart diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MASI Index, Melasma QoL Index, PGATimepoint: 2 weeks, 4 weeks, 6 weeks, 8 weeks
- Secondary Outcome Measures
Name Time Method CBC, LFT, KFT, Urine (R/M)Timepoint: 0 day, 14th day, 56th day